Abstract: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons. The cell differentiation induction of dextran sulfate has positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.

Abstract: The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.

Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Abstract: Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.

Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.

Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.

Abstract: A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da.

Abstract: Dextran sulfate in a range of 3500 and 9500 Da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration.

Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.

Abstract: Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating T-lymphocytes to treat metastatic cancer in a subject.

Abstract: A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.

Abstract: Dextran sulfate in a range of 3500 and 9500 Da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration.

Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.

Abstract: A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml.

Abstract: A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml.

Abstract: A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.

Abstract: Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating T-lymphocytes to treat metastatic cancer in a subject.

Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.